Upper Respiratory Tract Infections

Introduction to URTI Management

• Most URTIs are viral in origin and do not require antibiotics, with treatment focusing on symptomatic management and reserving antibiotics for specific bacterial complications, as recommended by the American Academy of Otolaryngology 1
• Inappropriate antibiotic use for URTIs is a major public health concern, with the American Academy of Otolaryngology emphasizing the need for responsible antibiotic use 1

Symptomatic Treatment

• Symptomatic treatment for URTIs includes adequate hydration, rest, over-the-counter analgesics for pain/fever, and saline nasal irrigation, with the goal of managing symptoms without unnecessary antibiotic use, as suggested by the European Society of Clinical Microbiology and Infectious Diseases 2
• Most URTIs are self-limiting and resolve within 7-10 days regardless of antibiotic use, highlighting the importance of watchful waiting and avoiding unnecessary antibiotic treatment, according to the European Society of Clinical Microbiology and Infectious Diseases 2
• For dry, bothersome cough in acute URTIs, dextromethorphan or codeine can be prescribed for symptomatic relief 3
• Expectorants, mucolytics, antihistamines, and bronchodilators should NOT be prescribed in acute URTIs in primary care settings as they lack evidence of effectiveness and may cause unnecessary side effects 3

Antibiotic Use

• Antibiotics should not be obtained without medical prescription or evidence-based indication, with the American Academy of Otolaryngology recommending against unnecessary antibiotic use 1
• The use of antibiotics for URTIs is not recommended, with a Grade B recommendation against their use, as stated by the European Society of Clinical Microbiology and Infectious Diseases 2
• Consider bacterial infection when symptoms persist >10-14 days, symptoms worsen after initial improvement, severe symptoms from onset, or fever persists for more than 3 days 2
• Initiate antibiotics when symptoms persisting >10-14 days, worsening symptoms after initial improvement, severe symptoms from onset, or purulent sputum with at least one other Anthonisen criterion 2
• First-line antibiotic options include amoxicillin-clavulanate, but alternative options such as cefuroxime-axetil or macrolides may be used in certain cases 4, 2
• The Infectious Diseases Society of America recommends amoxicillin-clavulanate as the first choice for URTI with persistent purulent sputum lasting 3 weeks, due to its coverage against common respiratory pathogens including beta-lactamase producing organisms, with a dosage of 875/125 mg twice daily for 7 days 2, 4
• Macrolides, such as azithromycin, should be considered if the patient has a beta-lactam allergy, atypical pathogens are suspected, or local pneumococcal resistance to macrolides is low, with azithromycin dosing at 500 mg once daily for 3 days or 500 mg on day 1 followed by 250 mg daily for 4 days 4, 5
• In areas with high antibiotic resistance, levofloxacin or moxifloxacin may be considered as alternative antibiotics for URTIs 3
• Earlier antibiotic intervention should be considered in patients aged >65 years with acute cough and comorbidities, patients with cardiac failure, insulin-dependent diabetes mellitus, serious neurological disorders, and immunocompromised patients 3

High-Risk Patients and Prevention

• High-risk patients for URTIs include those aged >65 years, with chronic obstructive pulmonary disease (COPD), diabetes, heart failure, those taking oral glucocorticoids, with a previous hospitalization in the past year, or antibiotic use in the previous month, and may exhibit general malaise, absence of upper respiratory symptoms, or confusion/diminished consciousness 4
• Patients with COPD, diabetes, heart failure, or immunocompromised status require closer monitoring and earlier intervention 4
• Annual influenza vaccination and pneumococcal vaccination according to current guidelines are recommended, although not explicitly cited, general preventive measures are supported by 4
• The American College of Physicians, the Centers for Disease Control and Prevention, and the World Health Organization recommend influenza vaccination yearly for persons at increased risk of complications, including age >65 years, institutionalization, chronic cardiac diseases, chronic pulmonary diseases, diabetes mellitus, chronic renal diseases, and pregnancy (second or third trimester during influenza season) 4

Follow-Up and Treatment Duration

• Patients should be advised to return if symptoms persist beyond 3 weeks 4, 3
• Clinical effects of antibiotic treatment should be expected within 3 days of initiation 3
• If no improvement is observed after 72 hours, consideration should be given to changing antibiotics, reevaluating the diagnosis, or possible referral to a hospital 2, 4
• Ensuring the complete course of antibiotics is taken, even if symptoms improve quickly, is crucial to prevent inadequate treatment duration 4
• The standard treatment duration for most antibiotics is 7 days, but azithromycin may have a sufficient treatment duration of 3-5 days due to its prolonged tissue half-life 5